- Home
- APPF vs PCVX Comparison
APPF vs PCVX Comparison
Compare APPF & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APPF | PCVX |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 7.0B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | APPF | PCVX |
|---|---|---|
| Price | $204.24 | $56.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $236.04 | $109.00 |
| AVG Volume (30 Days) | 217.5K | ★ 1.2M |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.36 | N/A |
| Revenue | ★ $950,822,000.00 | N/A |
| Revenue This Year | $18.19 | N/A |
| Revenue Next Year | $17.45 | N/A |
| P/E Ratio | $83.63 | ★ N/A |
| Revenue Growth | ★ 19.72 | N/A |
| 52 Week Low | $142.56 | $39.87 |
| 52 Week High | $264.87 | $65.00 |
Technical Indicators
Market Signals| Indicator | APPF | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 46.67 | 44.39 |
| Support Level | $200.57 | $52.18 |
| Resistance Level | $227.62 | $58.77 |
| Average True Range (ATR) | 7.13 | 2.19 |
| MACD | -2.23 | -0.27 |
| Stochastic Oscillator | 35.55 | 30.24 |
Price Performance
Historical ComparisonAbout APPF AppFolio Inc.
AppFolio Inc provides cloud-based software solutions for the real estate industry. Its property management software offers property managers an end-to-end solution to their business needs. The group's products include cloud-based property management software (Appfolio Property Manager). Its solutions are AppFolio Property Manager Core, AppFolio Property Manager Plus, and AppFolio Property Manager Max. It also offers value-added services, such as screening, risk mitigation, and electronic payment services. Its markets are Single-Family, Multifamily, Student Housing, Affordable Housing, Community Associations, Commercial, and Investment Management. The business activity of the firm predominantly functions in the United States and it generates revenue in the form of subscription fees.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.